Brigatinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with ALK mutations. It works by inhibiting the activity of the ALK protein, which is involved in cancer cell growth. It is typically used when other therapies, such as crizotinib, fail.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Brigatinib and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Brigatinib impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Brigatinib-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
